Respiratory Depression During an Analgosedation Combining Remifentanil and Ketamine in TCI for Oocyte Retrieval
NCT ID: NCT03458143
Last Updated: 2018-03-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
20 participants
OBSERVATIONAL
2018-02-12
2018-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness of Hypnosis Via Virtual Reality During Oocyte Retrieval
NCT05244538
Use of Ketamine Associate With an Opioid for Sedation in ICU
NCT01560390
Safety of Remifentanil Infusion
NCT01303627
Ketamine Infusion as Sedative Analgesic in Severe ARDS
NCT04818827
Inhaled Nitrous Oxide for the Prevention of Emergence Reaction During Ketamine Administration in Adults, a Pilot Study
NCT02145169
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The primary objective is to observe if with the addition of ketamine, it is possible to significantly reduce the dose of Remifentanil, in order to avoid episodes of respiratory depression caused by the opioid.
The secondary outcomes measured, will be the pain levels experienced by the patient, the sedation level, and the satisfaction of the patients after the procedure.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ketamine 150 ng/ml
The first group will receive the classical premedication with 2 mg of Midazolam. A bolus dose of Ketamine will be given, then to be titrated in TCI mode with a target concentration of 150 ng/ml. Right after, the Remifentanil TCI will be started at a concentration of 1 ng/ml and the procedure can begin.
Ketamine 150 ng/ml
conscious sedation in TCI-mode
Remifentanil
conscious sedation in TCI-mode
Oocyte retrieval
Oocyte retrieval for In Vitro Fertilization
ketamine 200 ng/ml
The second group will be treated in the exact way as the first, with the exception that the target effect site concentration is aimed at 200 ng/ml.
Remifentanil
conscious sedation in TCI-mode
Oocyte retrieval
Oocyte retrieval for In Vitro Fertilization
Ketamine 200 ng/ml
conscious sedation in TCI-mode
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ketamine 150 ng/ml
conscious sedation in TCI-mode
Remifentanil
conscious sedation in TCI-mode
Oocyte retrieval
Oocyte retrieval for In Vitro Fertilization
Ketamine 200 ng/ml
conscious sedation in TCI-mode
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* endometriosis
* contraindications to ketamine
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Erasme University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Luc Barvais
MD PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peres-Bota Iulia, student
Role: PRINCIPAL_INVESTIGATOR
Erasme hospital
Barvais Luc, MDPhD
Role: STUDY_DIRECTOR
Erasme hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Erasme University Hospital
Brussels, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P2018/016
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.